Top

Published in:

01-11-2020 | COVID-19 | Editorial

Rheumatologists in the COVID-19 era: will there be a new role for the rheumatologist in the care of rheumatic patients?

Authors: Jorge Morales-Torres, Francisco Javier Aceves-Ávila

Published in: Clinical Rheumatology | Issue 11/2020

Excerpt

The global disease burden of coronavirus disease 2019 (COVID-19) has risen to unprecedented levels never seen in this generation. A World Health Organization (WHO) situation report on July 4, 2020, presented a global figure of 10,992,324 cases, 523,011 deaths, and 212,326 new cases in the previous 24 h, with the Americas on the top of both confirmed and new cases as well as new deaths. Its distribution between countries and regions show big differences. While new cases and deaths have decreased sharply in countries like China and tend to decrease notably in some other countries (like Spain, Italy, and Germany), they are still high in several regions [1]. It is hard to foresee a near end for this ordeal, and one possible scenario is that COVID-19 will become an endemic condition [2]. Therefore, sociopolitical and daily life adaptations will be required, and the society will need to find ways to coexist with it, until a vaccine or cure become available. …

World Health Organization (2020) Coronavirus disease (COVID-19). Situation report-166. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200704-covid-19-sitrep-166.pdf?sfvrsn=6247972_2. Accessed July 4, 2020

Cobey A (2020) Modeling infectious disease dynamics. Science 368:713–714. https://doi.org/10.1126/science.abb5659CrossRefPubMed

Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, Yuan Q, Xiao X (2020) The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis 39:1011–1019. https://doi.org/10.1007/s10096-020-03874-zCrossRefPubMedPubMedCentral

Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, Agha M, Agha R (2020) The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg 78:185–193. https://doi.org/10.1016/j.ijsu.2020.04.018CrossRefPubMedPubMedCentral

Kohli P, Virani SS (2020) Surfing the waves of the COVID-19 pandemic as a cardiovascular clinician. Circulation 142:98–100. https://doi.org/10.1161/CIRCULATIONAHA.120.047901CrossRefPubMed

Doran MF, Crowson CS, Pond GR, O’Fallon W, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293. https://doi.org/10.1002/art.10524CrossRefPubMed

Franklin J, Lunt M, Bunn D, Symmons D, Silman A (2007) Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 66:308–312. https://doi.org/10.1136/ard.2006.057265CrossRefPubMed

Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11(3):229. https://doi.org/10.1186/ar2669CrossRefPubMedPubMedCentral

Matsumoto Y, Sada K, Takano M et al (2011) Risk factors for infection in patients with remitted rheumatic diseases treated with glucocorticoids. Acta Med Okayama 65:329–334PubMed

10.

Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, Michaud K (2019) Serious infection risk in rheumatoid arthritis compared with noninflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open 5:e000935. https://doi.org/10.1136/rmdopen-2019-000935CrossRefPubMedPubMedCentral

11.

Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR (2011) Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306:2331–2339. https://doi.org/10.1001/jama.2011.1692CrossRefPubMedPubMedCentral

12.

Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, Ladefoged de Thurah A, Landewé R, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O (2019) Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5(2):e001041. https://doi.org/10.1136/rmdopen-2019-001041CrossRefPubMedPubMedCentral

13.

Glück T, Müller-Ladner U (2008) Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 46:1459–1465. https://doi.org/10.1086/587063CrossRefPubMed

14.

Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA (2020) Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis:annrheumdis-2020-217322. https://doi.org/10.1136/annrheumdis-2020-217322

15.

Cheng C, Li C, Zhao T, Yue J, Yang F, Yan Y, Liu X (2020) COVID-19 with rheumatic diseases: a report of 5 cases. Clin Rheumatol 39:2025–2029. https://doi.org/10.1007/s10067-020-05160-xCrossRefPubMedPubMedCentral

16.

Michaud K, Wipfle K, Shaw Y et al (2020) Experiences of patients with rheumatic diseases in the US during early days of the COVID-19 pandemic. ACR Open Rheumatol 2:335–343. https://doi.org/10.1002/acr2.11148CrossRefPubMedPubMedCentral

17.

Quartuccio L, Valent F, Pasut E, Tascini C, DeVita S (2020) Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine. https://doi.org/10.1016/j.jbspin.2020.05.003

18.

Favalli EG, Mont S, Ingegnoli F, Balduzzi S, Caporalli R, Montecucco C (2020) Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheum. https://doi.org/10.1002/art.41388

19.

Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, Gomez-Reino J, Alvaro-Gracia JM, BIOBADASER study group (2020) Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis 79:988–990. https://doi.org/10.1136/annrheumdis-2020-217948CrossRefPubMed

20.

Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79:667–668. https://doi.org/10.1136/annrheumdis-2020-217424CrossRefPubMed

21.

Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, Barrelet A, Chauvet C, Chazal T, Delahousse M, Devaux M, Euvrard R, Fadlallah J, Florens N, Haroche J, Hié M, Juillard L, Lhote R, Maillet T, Richard-Colmant G, Palluy JB, Pha M, Perard L, Remy P, Rivière E, Sène D, Sève P, Morélot-Panzini C, Viallard JF, Virot JS, Benameur N, Zahr N, Yssel H, Godeau B, Amoura Z (2020) Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 79:837–839. https://doi.org/10.1136/annrheumdis-2020-217566CrossRefPubMed

22.

Wallace B, Washer L, Marder W, Kahlenberg JM (2020) Patients with lupus with COVID-19: University of Michigan experience. Ann Rheum Dis:annrheumdis-2020-217794. https://doi.org/10.1136/annrheumdis-2020-217794

23.

Favalli EG, Ingegnol F, De Lucia O et al (2020) COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev 102523:102523. https://doi.org/10.1016/j.autrev.2020.102523CrossRef

24.

McInnes IB (2020) COVID-19 and rheumatology: first steps towards a different future? Ann Rheum Dis 79:551–552. https://doi.org/10.1136/annrheumdis-2020-217494CrossRefPubMed

25.

Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, Sufka P, Grainger R, Wallace Z, Bhana S, Sirotich E, Liew J, Hausmann JS, Costello W, Robinson P, Machado PM, Yazdany J, COVID-19 Global Rheumatology Alliance Steering Committee (2020) Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2:e250–e253. https://doi.org/10.1016/s2665-9913(20)30095-3CrossRefPubMedPubMedCentral

26.

Sirotich E, Dillingham S, Grainger R, Hausmann JS (2020) Capturing patient-reported outcomes during the COVID-19 pandemic: development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey. Arthritis Care Res 72:871–873. https://doi.org/10.1002/acr.24257CrossRef

27.

Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79:859–866. https://doi.org/10.1136/annrheumdis-2020CrossRefPubMed

28.

Fragoulis GE, Evangelatos G, Arida A, Bournia VK, Fragiadaki K, Karamanakos A, Kravvariti E, Laskari K, Panopoulos S, Pappa M, Tektonidou MG, Sfikakis PP (2020) Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Ann Rheum. https://doi.org/10.1136/annrheumdis-2020-217935 annrheumdis-2020-217935

29.

Schulze-Koops H, Krueger K, Specker C (2020) No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV- 2. Response to: ‘Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis et al. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217987 annrheumdis-2020-217987

30.

Schulze-Koops H, Specker C, Iking-Konert C et al (2020) Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/Covid-19 pandemic. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217628

31.

Landewe R, Machado P, Kroon F et al (2020) EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2, April 2020 version. Ann Rheum Dis 79:851–858. https://doi.org/10.1136/annrheumdis-2020-217877CrossRefPubMed

32.

Mikuls TR, Johnson SR, Fraenkl L et al (2020) American College of Rheumatology guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic. Arthritis Rheum 72:1241–1251. https://doi.org/10.1002/art.41301CrossRef

33.

Mobasheri A (2020) COVID-19, osteoarthritis and women's health. Case Rep Women’s Health 27:e00207. https://doi.org/10.1016/j.crwh.2020.e00207CrossRef

34.

Girgis CM, Clifton-Bligh RJ (2020) Osteoporosis in the age of COVID-19. Osteoporos Int 71:1189–1191. https://doi.org/10.1007/s00198-020-05413-0CrossRef

35.

Laura E, Wong LE, Hawkins JE, Langness S et al (2020) Where are all the patients? Addressing Covid-19 fear to encourage sick patients to seek emergency care. NEJM Catalyst. https://doi.org/10.1056/CAT.20.0193

36.

Sarzi-Puttini P, Ventura D, Antivalle M et al (2020) What did COVID-19 do to the organization of Italian rheumatology? The examples of Luigi Sacco University Hospital and the local health district of ATS Sardegna: the two faces of the same coin. Beyond Rheumatol 2(#37)

37.

Thwaites G, Taviner M, Gant V (1997) The English sweating sickness, 1485 to 1551. N Engl J Med 336:580–582CrossRefPubMed

38.

Calina D, Docea AO, Petrakis D et al (2020) Towards effective COVID-19 vaccines: updates, perspectives and challenges (Review). Int J Mol Med 46:3–16. https://doi.org/10.3892/ijmm.2020.4596CrossRefPubMedPubMedCentral

39.

World Health Organization (2020) COVID-19: Operational guidance for maintaining essential health services during an outbreak: interim guidance. 25 March 2020 https://apps.who.int/iris/handle/10665/331561. License: CC BY-NC-SA 3.0 IGO. Accessed 23 June 2020

40.

van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, Munster VJ (2020) Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 382:1564–1567. https://doi.org/10.1056/NEJMc2004973CrossRefPubMed

41.

Dellanno C, Vega Q, Boesenberg D (2009) The antiviral action of common household disinfectants and antiseptics against murine hepatitis virus, a potential surrogate for SARS coronavirus. Am J Infect Control 37:649–652. https://doi.org/10.1016/j.ajic.2009.03.012CrossRefPubMedPubMedCentral

42.

C-Hung C, C-Hsien C, C-Han C (2020) Can universal masking help with our recovery from the COVID-19 pandemic? Int J Surg 79:125–126. https://doi.org/10.1016/j.ijsu.2020.05.058CrossRef

43.

Chu DE, Aki EA, Duda S et al (2020) Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-Cov-2 and COVID-19: a systematic review and meta-analysis. Lancet 395:1973–1987. https://doi.org/10.1016/S0140-6736(20)31142-9CrossRefPubMedPubMedCentral

44.

Baricco A (2019) The game. Editorial Anagrama S.A. 1^st. ed. Barcelona

45.

Shorter E (1985).Bedside manners. The troubled history of doctors and patients. Simon and Schuster, 1^st. ed. New York

46.

Anderson JK, Zimmerman L, Caplan L, Michaud K (2011) Measures of rheumatoid arthritis disease activity. Arthritis Care Res 63:S14–S36. https://doi.org/10.1002/acr.20621CrossRef

47.

Heegaard C, Dreyer L, Egsmose C, Madsen OR (2013) Test–retest reliability of the Disease Activity Score 28 CRP (DAS28-CRP), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen joints. Clin Rheumatol 32:1493–1500. https://doi.org/10.1007/s10067-013-2300-9CrossRefPubMed

48.

Taylor PC (2020) Adopting PROs in virtual and outpatient management of RA. Nat Rev Rheum 16:477–478. https://doi.org/10.1038/s41584-020-0449-6CrossRef

49.

Moreno-Torres LA, Ventura-Alfaro CE, Aceves-Avila FJ (2020) Cross-cultural adaptation and validation of the Gait, Arms, Legs, Spine locomotor screening test for detecting musculoskeletal disorders in Mexican adults. Int J Rheum Dis 00:1–7. https://doi.org/10.1111/1756-185X.13849CrossRef

50.

Piga M, Cangemi I, Mathieu A, Cauli A (2017) Telemedicine for patients with rheumatic diseases: systematic review and proposal for research agenda. Semin Arthritis Rheum 47:121–128. https://doi.org/10.1016/j.semarthrit.2017.03.014CrossRefPubMed

51.

https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet. Accessed 23 June 2020

52.

https://pubmed.ncbi.nlm.nih.gov/?term=COVID-19. Accessed 23 June 2020

53.

Yeo-Teh NSL, Tang BL (2020) An alarming retraction rate for scientific publications on coronavirus disease 2019 (COVID-19). Account Res:1–7. https://doi.org/10.1080/08989621.2020.1782203

54.

Brainard J (2020) New tools aim to tame pandemic paper tsunami. Science 368:924–925. https://doi.org/10.1126/science.368.6494.924CrossRefPubMed

55.

Torales J, O'Higgins M, Castaldelli-Maia JM, Ventriglio A (2020) The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry 66:317–320. https://doi.org/10.1177/0020764020915212CrossRefPubMed

Title: Rheumatologists in the COVID-19 era: will there be a new role for the rheumatologist in the care of rheumatic patients?
Authors: Jorge Morales-Torres
Francisco Javier Aceves-Ávila
Publication date: 01-11-2020
Publisher: Springer International Publishing
Keyword: COVID-19
Published in: Clinical Rheumatology / Issue 11/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05380-1

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2020

When rheumatoid arthritis is mentioned, should only dryness come to mind?

LncRNA CTBP1-AS2 is upregulated in osteoarthritis and increases the methylation of miR-130a gene to inhibit chondrocyte proliferation

Orofacial manifestations of SAPHO syndrome: a systematic review of case reports

Numano type V Takayasu arteritis patients are more prone to have coronary artery involvement

Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment

Temporal relationship between idiopathic inflammatory myopathies and malignancies and its mortality: a nationwide population-based study

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage